US 12,042,284 B2
Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses
Jia Yao, Tarzana, CA (US); Daniel E. Pesantez, Canoga Park, CA (US); Anuradha Biswas Bhatia, McLean, VA (US); Akhil Srinivasan, Sherman Oaks, CA (US); Guangping Zhang, Calabasas, CA (US); Andrea Varsavsky, Santa Monica, CA (US); and Raghavendhar Gautham, Los Angeles, CA (US)
Assigned to MEDTRONIC MINIMED, INC., Northridge, CA (US)
Filed by MEDTRONIC MINIMED, INC., Northridge, CA (US)
Filed on Jan. 23, 2018, as Appl. No. 15/878,313.
Prior Publication US 2019/0223771 A1, Jul. 25, 2019
Int. Cl. A61B 5/1486 (2006.01); A61B 5/145 (2006.01); A61L 31/04 (2006.01); A61L 31/14 (2006.01); C09D 5/16 (2006.01); C12Q 1/00 (2006.01); C12Q 1/26 (2006.01); C12Q 1/54 (2006.01); A61B 5/00 (2006.01)
CPC A61B 5/14865 (2013.01) [A61B 5/1451 (2013.01); A61B 5/14532 (2013.01); A61L 31/04 (2013.01); A61L 31/14 (2013.01); C09D 5/1681 (2013.01); C12Q 1/006 (2013.01); C12Q 1/26 (2013.01); C12Q 1/54 (2013.01); A61B 5/41 (2013.01); A61L 2400/18 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method of avoiding an inflammatory response to an implanted medical device comprising implanting the implantable medical device having a surface adapted to contact an in vivo environment, the surface comprising a polyimide composition having the following characteristics:
a carbon-to-oxygen ratio greater than 5 to 1;
a surface hydrophobicity of between 75° and 90°;
a surface topography characterized by at least one of (a)-(c):
(a) grooves having an average peak-to-valley height of between 0.3 μm and 5 μm;
(b) wells having an average peak-to-valley height of between 1 μm and 2 μm; and
(c) grids having an average peak-to-valley height of between 2 μm and 4 μm;
wherein:
the surface avoids the inflammatory response by having surface characteristics such that when exposed to the surface comprising the polymer composition, RAW264.7 macrophages are influenced to differentiate into an anti-inflammatory (M2) phenotype.